Literature DB >> 23411915

Small Molecule Ligands For Active Targeting Of TrkC-expressing Tumor Cells.

Eunhwa Ko1, Anyanee Kamkaew, Kevin Burgess.   

Abstract

A small molecule motif was used in "active targeting" to deliver cytotoxic substances into tumor cells that express the TrkC receptor. Underlying this study was the hypothesis that internalization of targeted conjugates into cells would be facile if mediated by receptor binding and receptor-ligand internalization. Initial experiments using 6-mercaptopurine gave encouraging data, but demonstrated the importance of maintaining solubility and high cytotoxicity. Conjugates of the targeting agent with a cytotoxic rosamine (similar to a rhodamine) were more successful. Targeting of TrkC was observed, validated in a series of competition experiments featuring other TrkC ligands, and accumulation into lysosomes was observed, as expected for receptor-mediated internalization.

Entities:  

Keywords:  TrkC; cancer; neurotrophin; small molecule ligand; targeting

Year:  2012        PMID: 23411915      PMCID: PMC3568983          DOI: 10.1021/ml300227d

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

1.  Lectin-mediated drug targeting: selection of valency, sugar type (Gal/Lac), and spacer length for cluster glycosides as parameters to distinguish ligand binding to C-type asialoglycoprotein receptors and galectins.

Authors:  S André; B Frisch; H Kaltner; D L Desouza; F Schuber; H J Gabius
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

3.  Sorting of internalized neurotrophins into an endocytic transcytosis pathway via the Golgi system: Ultrastructural analysis in retinal ganglion cells.

Authors:  R Butowt; C S von Bartheld
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

4.  Gangliosides activate Trk receptors by inducing the release of neurotrophins.

Authors:  Stuart J Rabin; Alessia Bachis; Italo Mocchetti
Journal:  J Biol Chem       Date:  2002-10-17       Impact factor: 5.157

5.  Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha.

Authors:  C Song; S Liao
Journal:  Endocrinology       Date:  2000-11       Impact factor: 4.736

6.  New cytotoxic rosamine derivatives selectively accumulate in the mitochondria of cancer cells.

Authors:  Siang Hui Lim; Liangxing Wu; Kevin Burgess; Hong Boon Lee
Journal:  Anticancer Drugs       Date:  2009-07       Impact factor: 2.248

7.  GABA B receptor is a novel drug target for pancreatic cancer.

Authors:  Hildegard M Schuller; Hussein A N Al-Wadei; Mourad Majidi
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

8.  Formation of 6-thioguanine and 6-mercaptopurine from their 9-alkyl derivatives in mice.

Authors:  J A Nelson; E Vidale
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

Review 9.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.

Authors:  Philip S Low; Walter A Henne; Derek D Doorneweerd
Journal:  Acc Chem Res       Date:  2007-07-27       Impact factor: 22.384

Review 10.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

View more
  3 in total

1.  Click-Addressable Cassette for Photoaffinity Labeling.

Authors:  Bosheng Zhao; Kevin Burgess
Journal:  ACS Med Chem Lett       Date:  2018-01-24       Impact factor: 4.345

2.  TrkC-Targeted Kinase Inhibitors And PROTACs.

Authors:  Bosheng Zhao; Kevin Burgess
Journal:  Mol Pharm       Date:  2019-09-12       Impact factor: 4.939

3.  Double-targeting using a TrkC ligand conjugated to dipyrrometheneboron difluoride (BODIPY) based photodynamic therapy (PDT) agent.

Authors:  Anyanee Kamkaew; Kevin Burgess
Journal:  J Med Chem       Date:  2013-09-24       Impact factor: 7.446

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.